Exclusion Criteria:~* MMSE score 0-25, indicating more than subtle cognitive abnormalities~* CDR-SB score > 0,
indicating functional impairment~* Clinical diagnosis of any non-Alzheimer's disease (AD) type of mild
cognitive impairment (MCI) or dementia~* Taking pharmaceutical anti-AÎ² monoclonal antibodies (i.e., Leqembi,
Aduhelm).~* Participation in another clinical study with an investigational product during the last 90 days.~*
Presence of hepatic disease or kidney disease~* Clinically significant or unstable hematologic, cardiovascular,
pulmonary, gastrointestinal, endocrine metabolic, or other systemic disease.~* Diagnosis of gastrointestinal or
stomach condition including but not limited to irritable bowel syndrome (IBS), ulcerative colitis, peptic
ulcers, Crohn's disease, gastroesophageal reflux disease, gastritis, severe dyspepsia, and intestinal
malabsorption.~* Clinically significant abnormal values in hematology, coagulation and platelet function,
clinical chemistry, or urinalysis at screening (such as those with prolonged prothrombin time (PT), anemia, low
neutrophil or platelet count, elevated liver function tests, low glomerular filtration rate).
